Viral infection after renal transplantation: Surveillance and management

被引：97

作者：

Weikert, Blair C. ^{[1
]}

Blumberg, Emily A. ^{[1
]}

机构：

[1] Hosp Univ Penn, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA

来源：

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2008年 / 3卷

关键词：

D O I：

10.2215/CJN.02900707

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Viral infections remain a significant cause of morbidity and mortality following renal transplantation. Although cytomegalovirus is the most common opportunistic pathogen seen in transplant recipients, numerous other viruses have also affected outcomes. In some cases, preventive measures such as pretransplant screening, prophylactic antiviral therapy, or post transplant viral monitoring may limit the impact of these infections. Recent advances in laboratory monitoring and antiviral therapy have improved outcomes. This review will summarize the major viral infections seen following transplant and discuss strategies for prevention and management of these potential pathogens.

引用

页码：S76 / S86

页数：11

共 106 条

[31] Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: Analysis of United Network of Organ Sharing database between 1994 and 1999 [J].

Fong, TL ;

Bunnapradist, S ;

Jordan, SC ;

Cho, YW .

TRANSPLANTATION, 2002, 73 (01) :85-89

[32] Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C [J].

Fontaine, H ;

Vallet-Pichard, A ;

Equi-Andrade, C ;

Nalpas, B ;

Verkarre, V ;

Chaix, ML ;

Lebray, P ;

Sobesky, R ;

Serpaggi, J ;

Kreis, H ;

Pol, S .

TRANSPLANTATION, 2004, 78 (06) :853-857

[33] The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection [J].

Fornairon, S ;

Pol, S ;

Legendre, C ;

Carnot, F ;

MamzerBruneel, MF ;

Brechot, C ;

Kreis, H .

TRANSPLANTATION, 1996, 62 (02) :297-299

[34] Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients [J].

Funch, DP ;

Walker, AM ;

Schneider, G ;

Ziyadeh, NJ ;

Pescovitz, MD .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (12) :2894-2900

[35] CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients [J].

Green, M. ;

Michaels, M. G. ;

Katz, B. Z. ;

Burroughs, M. ;

Gerber, D. ;

Shneider, B. L. ;

Newell, K. ;

Rowe, D. ;

Reyes, J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) :1906-1912

[36] Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B [J].

Hadziyannis, SJ ;

Papatheodoridis, GV ;

Dimou, E ;

Laras, A ;

Papaioannou, C .

HEPATOLOGY, 2000, 32 (04) :847-851

[37]

HANTO DW, 1995, ANNU REV MED, V46, P381

[38] The natural course of cytomegalovirus infection and disease in renal transplant recipients [J].

Hartmann, Anders ;

Sagedal, Solbjorg ;

Hjelmesaeth, Joran .

TRANSPLANTATION, 2006, 82 (02) :S15-S17

[39] Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations [J].

Hirsch, HH ;

Brennan, DC ;

Drachenberg, CB ;

Ginevri, F ;

Gordon, J ;

Limaye, AP ;

Mihatsch, MJ ;

Nickeleit, V ;

Ramos, E ;

Randhawa, P ;

Shapiro, R ;

Steiger, J ;

Suthanthiran, M ;

Trofe, J .

TRANSPLANTATION, 2005, 79 (10) :1277-1286

[40] Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials [J].

Hodson, EM ;

Jones, CA ;

Webster, AC ;

Strippoli, GF ;

Barclay, PG ;

Kable, K ;

Vimalachandra, D ;

Craig, JC .

LANCET, 2005, 365 (9477) :2105-2115

← 1 2 3 4 5 6 7 8 9 10 →